Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition
Abstract Dysregulated lipid metabolism is a prominent feature of prostate cancer that is driven by androgen receptor (AR) signaling. Herein, we used quantitative mass spectrometry to define the “lipidome” in prostate tumors with matched benign tissues (n=21), independent tissues (n=47), and primary prostate explants cultured with a clinical AR antagonist, enzalutamide (n=43). Significant differences in lipid composition were detected and spatially visualized in tumors compared to matched benign samples. Notably, tumors featured higher proportions of monounsaturated lipids overall and elongated fatty acid chains in phosphatidylinositol and phosphatidylserine lipids. Significant associations between lipid profile and malignancy were validated in unmatched samples, and PL composition was characteristically altered in patient tissues that responded to AR inhibition. Importantly, targeting of altered tumor-related lipid features, via inhibition of acetyl CoA carboxylase 1, significantly reduced cellular proliferation in tissue explants (n=13). This first characterization of the prostate cancer lipidome in clinical tissues revealed enhanced fatty acid synthesis, elongation and desaturation as tumor-defining features, with potential for therapeutic targeting..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
bioRxiv.org - (2021) vom: 15. Dez. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Butler, Lisa M. [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1101/2020.10.27.356634 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI019234260 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI019234260 | ||
| 003 | DE-627 | ||
| 005 | 20230429084939.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201030s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.10.27.356634 |2 doi | |
| 035 | |a (DE-627)XBI019234260 | ||
| 035 | |a (biorXiv)10.1101/2020.10.27.356634 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Butler, Lisa M. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Dysregulated lipid metabolism is a prominent feature of prostate cancer that is driven by androgen receptor (AR) signaling. Herein, we used quantitative mass spectrometry to define the “lipidome” in prostate tumors with matched benign tissues (n=21), independent tissues (n=47), and primary prostate explants cultured with a clinical AR antagonist, enzalutamide (n=43). Significant differences in lipid composition were detected and spatially visualized in tumors compared to matched benign samples. Notably, tumors featured higher proportions of monounsaturated lipids overall and elongated fatty acid chains in phosphatidylinositol and phosphatidylserine lipids. Significant associations between lipid profile and malignancy were validated in unmatched samples, and PL composition was characteristically altered in patient tissues that responded to AR inhibition. Importantly, targeting of altered tumor-related lipid features, via inhibition of acetyl CoA carboxylase 1, significantly reduced cellular proliferation in tissue explants (n=13). This first characterization of the prostate cancer lipidome in clinical tissues revealed enhanced fatty acid synthesis, elongation and desaturation as tumor-defining features, with potential for therapeutic targeting. | ||
| 700 | 1 | |a Mah, Chui Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Machiels, Jelle |e verfasserin |4 aut | |
| 700 | 1 | |a Vincent, Andrew D. |e verfasserin |4 aut | |
| 700 | 1 | |a Irani, Swati |e verfasserin |4 aut | |
| 700 | 1 | |a Mutuku, Shadrack |e verfasserin |4 aut | |
| 700 | 1 | |a Spotbeen, Xander |e verfasserin |4 aut | |
| 700 | 1 | |a Bagadi, Muralidhararao |e verfasserin |4 aut | |
| 700 | 1 | |a Waltregny, David |e verfasserin |4 aut | |
| 700 | 1 | |a Moldovan, Max |e verfasserin |4 aut | |
| 700 | 1 | |a Dehairs, Jonas |e verfasserin |4 aut | |
| 700 | 1 | |a Vanderhoydonc, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Bloch, Katarzyna |e verfasserin |4 aut | |
| 700 | 1 | |a Das, Rajdeep |e verfasserin |4 aut | |
| 700 | 1 | |a Stahl, Jurgen |e verfasserin |4 aut | |
| 700 | 1 | |a Kench, James |e verfasserin |4 aut | |
| 700 | 1 | |a Gevaert, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Derua, Rita |e verfasserin |4 aut | |
| 700 | 1 | |a Waelkens, Etienne |e verfasserin |4 aut | |
| 700 | 1 | |a Nassar, Zeyad D. |e verfasserin |4 aut | |
| 700 | 1 | |a Selth, Luke A. |e verfasserin |4 aut | |
| 700 | 1 | |a Trim, Paul J. |e verfasserin |4 aut | |
| 700 | 1 | |a Snel, Marten F. |e verfasserin |4 aut | |
| 700 | 1 | |a Lynn, David J. |e verfasserin |4 aut | |
| 700 | 1 | |a Tilley, Wayne D. |e verfasserin |4 aut | |
| 700 | 1 | |a Horvath, Lisa G. |e verfasserin |4 aut | |
| 700 | 1 | |a Centenera, Margaret M. |e verfasserin |4 aut | |
| 700 | 1 | |a Swinnen, Johannes V. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 15. Dez. |
| 773 | 1 | 8 | |g year:2021 |g day:15 |g month:12 |
| 856 | 4 | 0 | |u https://doi.org/10.1158/0008-5472.can-20-3863 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.10.27.356634 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 15 |c 12 | ||
| 953 | |2 045F |a 570 | ||